My Take: The market likes the deal, but ENZ's chart is ugly. This stock has had a rough 12 months, and I'm not sure if this news will give it the boost it needs to break out of its long-term funk.
Histogen [HSTO] - Last Close: $0.8623
Histogen is pushing higher after a Thursday evening announcement.
The clinical-stage therapeutics company was issued a U.S. patent that will cover its portfolio of anti-inflammatory caspase inhibitors, such as CTS-2090.
Histogen was awarded Patent No. 11,579,703 titled, "âCaspase Inhibitors and Methods of Use Thereof,â from the US Patent & Trademark Office.
This patent notes that Histogen's CTS-2090 has demonstrated potent oral activity in a well characterized model of ulcerative colitis.
A Histogen spokesperson said the patent "builds upon Histogenâs growing proprietary caspase inhibitor portfolio," which includes another patent issued in September 2022.
HSTO is one of this morning's top stocks with a 32.2% gain on active trading volume.
My Take: If Histogen continues to acquire intellectual property at this rate, it could become a Big Pharma buyout target. This stock could be worth keeping an eye on in the weeks and months ahead.
Hub Cyber Security [HUBC] - Last Close: $2.39
Hub Cyber is running hot in the wake of a recent announcement.
Earlier this week, the cybersecurity company announced it had made a $4 million sale of its common stock to PIPE investors at a price of $10 per share.
Shares of HUBC have been rallying since the announcement was made. Since Monday's close, shares are up 58%.
Today, this stock is adding to its gains, despite no additional news to explain the push higher.
HUBC is up 23.4% in today's premarket, and it's one of this morning's most active stocks.
My Take: There has been a lot of activity in HUBC since it made its market debut earlier in the month. This stock could have long-term growth potential, as it seems to have Wall Street behind it.
